Everything below concerns Preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
==== Near-CDP ==== Continuous Data Protection (CDP) refers to a backup that instantly saves a copy of every change made to the data. This allows restoration of data to any point in time and is the most comprehensive and advanced data protection. Near-CDP backup applications—often marketed as "CDP"—automatically take incremental backups at a specific interval, for example every 15 minutes, one hour, or 24 hours. They can therefore only allow restores to an interval boundary. Near-CDP backup applications use journaling and are typically based on periodic "snapshots", read-only copies of the data frozen at a particular point in time. Near-CDP (except for Apple Time Machine) intent-logs every change on the host system, often by saving byte or block-level differences rather than file-level differences. This backup method differs from simple disk mirroring in that it enables a roll-back of the log and thus a restoration of old images of data. Intent-logging allows precautions for the consistency of live data, protecting self-consistent files but requiring applications "be quiesced and made ready for backup." Near-CDP is more practicable for ordinary personal backup applications, as opposed to true CDP, which must be run in conjunction with a virtual machine or equivalent and is therefore generally used in enterprise client-server backups.
== Structure == Ergothioneine is a thiourea derivative of the betaine of histidine and contains a sulfur atom bonded to the 2-position of the imidazole ring. Typical of thioureas, ergothioneine is less reactive than typical thiols such as glutathione towards alkylating agents like maleimides. It also resists oxidation by air. However, ergothioneine can be slowly oxidized over several days to the disulfide form in acidic solutions.
Nylon was first used commercially in a nylon-bristled toothbrush in 1938, followed more famously in women's stockings or "nylons" which were shown at the 1939 New York World's Fair and first sold commercially in 1940, whereupon they became an instant commercial success with 64 million pairs sold during their first year on the market. During World War II, almost all nylon production was diverted to the military for use in parachutes and parachute cord. Wartime uses of nylon and other plastics greatly increased the market for the new materials. The production of nylon required interdepartmental collaboration between three departments at DuPont: the Department of Chemical Research, the Ammonia Department, and the Department of Rayon. Some of the key ingredients of nylon had to be produced using high pressure chemistry, the main area of expertise of the Ammonia Department. Nylon was considered a "godsend to the Ammonia Department", which had been in financial difficulties. The reactants of nylon soon constituted half of the Ammonia Department's sales and helped them come out of the period of the Great Depression by creating jobs and revenue at DuPont. DuPont's nylon project demonstrated the importance of chemical engineering in industry, helped create jobs, and furthered the advancement of chemical engineering techniques. In fact, it developed a chemical plant that provided 1800 jobs and used the latest technologies of the time, which are still used as a model for chemical plants today.
Because PCR amplifies the regions of DNA that it targets, PCR can be used to analyze extremely small amounts of sample. This is often critical for forensic analysis, when only a trace amount of DNA is available as evidence. PCR may also be used in the analysis of ancient DNA that is tens of thousands of years old. These PCR-based techniques have been successfully used on animals, such as a forty-thousand-year-old mammoth, and also on human DNA, in applications ranging from the analysis of Egyptian mummies to the identification of a Russian tsar and the body of English king Richard III. Quantitative PCR or real-time PCR (qPCR not to be confused with RT-PCR) methods allow the estimation of the amount of a given sequence present in a sample—a technique often applied to quantitatively determine levels of gene expression. The MIQE guidelines written by professors Stephen Bustin, Michael Pfaffl, Mikael Kubista and colleagues outline how qPCR experiments shall be performed and the results reported. Quantitative PCR is an established tool for DNA quantification that measures the accumulation of DNA product after each round of PCR amplification. qPCR allows the quantification and detection of a specific DNA sequence in real time since it measures concentration while the synthesis process is taking place. There are two methods for simultaneous detection and quantification. The first method consists of using fluorescent dyes that are retained nonspecifically in between the double strands.
Sources: en.wikipedia.org
Ribonucleoproteins (RNPs): complexes made up of RNAs and RNA-binding proteins (RBPs) NHS-diazirine (SDA): a cell permeable crosslinking reagent. SDA contains two reactive groups - a diazirine and a succinimidyl ester. The reaction between succinimidyl esters and amine groups (e.g. lysine side chains) results in peptide bonds (or amide bonds). When exposed to UV light with a wavelength of 365 nm, an intermediate broadly reactive toward nucleotide riboses and bases is formed. As a result, proteins are crosslinked with RNA by the SDA linker. Mutational profiling (MaP): a method using reverse transcriptase with relaxed fidelity to incorporate modified residues at protein-RNA binding sites.
== Further reading == Bowen, W. Richard; Mohammad, A. Wahab (Aug 1998). "Diafiltration by nanofiltration: Prediction and optimization". AIChE Journal. 44 (8): 1799–1812. Bibcode:1998AIChE..44.1799R. doi:10.1002/aic.690440811. Limayem, Imène; Charcosset, Catherine; Fessi, Hatem (2004). "Purification of nanoparticle suspensions by a concentration/diafiltration process". Separation and Purification Technology. 38 (1): 1–9. doi:10.1016/j.seppur.2003.10.002. Sheth, Jignesh P.; et al. (2003). "Nanofiltration-based diafiltration process for solvent exchange in pharmaceutical manufacturing". Journal of Membrane Science. 211 (2): 251–261. doi:10.1016/s0376-7388(02)00423-4.
District Court judicial nominees who Kennedy believed were not qualified: Jeff Mateer, Brett Talley, and Matthew S. Petersen. The White House withdrew all three nominations. On December 13, 2017, during Petersen's confirmation hearing before the Senate Judiciary Committee, Kennedy asked Petersen about basic legal procedure, whether he knew what the Daubert standard was and what a motion in limine was. Petersen struggled to answer. Kennedy also voted against the nomination of Gregory G. Katsas to the D.C. Circuit, but Katsas was confirmed. On April 7, 2017, Kennedy voted to confirm Neil Gorsuch to the United States Supreme Court. Kennedy participated in Gorsuch's confirmation as a member of the Judiciary Committee. During the confirmation process, Kennedy said, “Neil Gorsuch is obviously very well-qualified based on his education and background, but I want to know what’s in his heart. I want to know what he thinks about past Supreme Court decisions and how the justices reached those decisions. I want to know whether he thinks personal preferences have a role in the judicial decision-making. I want to know if he knows the name of the person who cleans his office. Also, I'm rather fond of the U.S. Constitution, and I want to make sure he is, too." On October 6, 2018, Kennedy voted to confirm Brett Kavanaugh to the Supreme Court. As a member of the Judiciary Committee, Kennedy participated in Kavanaugh's contentious nomination hearing after Christine Blasey Ford accused Kavanaugh of sexual assault.
Sources: en.wikipedia.org
10 January – British Post Office scandal: Prime Minister Rishi Sunak announces that emergency legislation would be brought through Parliament to "swiftly exonerate and compensate victims" of the Post Office scandal in England and Wales. First Minister of Scotland Humza Yousaf confirms those in Scotland convicted because of the scandal would also be cleared, and that he would work with the UK government to bring this about. 11 January – The Liberal Democrats ask Ofcom to investigate GB News over alleged bias in its coverage of the Post Office scandal, including what the party's deputy leader, Daisy Cooper, describes as "a fictitious monologue" Nigel Farage delivered about Sir Ed Davey, which she says contained "a number of factual inaccuracies". First Minister of Scotland Humza Yousaf confirms that the Scottish Government would "in essence replicate" the law in England and Wales banning unlicensed ownership of American XL bully dogs. Sunak authorises joint UK–US air strikes against Houthi rebels following attacks against cargo shipping targets in the Red Sea. 12 January – The Liberal Democrats, Scottish National Party and Plaid Cymru call for a recall of parliament to enable a vote on RAF involvement in the air strikes against Houthi rebels in Yemen, since Parliament had already risen for the weekend when Sunak authorised the UK's participation. Sunak authorises talks between the Labour Party and the civil service ahead of a general election later in the year to ensure a smooth transition if Labour becomes the party of government.
Plutonium (specifically, plutonium-238) was first produced, isolated, and then chemically identified between December 1940 and February 1941 by Glenn T. Seaborg, Edwin McMillan, Emilio Segrè, Joseph W. Kennedy, and Arthur Wahl by deuteron bombardment of uranium in the 60-inch (150 cm) cyclotron at the Berkeley Radiation Laboratory at the University of California, Berkeley. Neptunium-238 was created directly by the bombardment but decayed by beta emission with a half-life of a little over two days, which indicated the formation of element 94. The first bombardment took place on December 14, 1940, and the new element was first identified through oxidation on the night of February 23–24, 1941. A paper documenting the discovery was prepared by the team and sent to the journal Physical Review in March 1941, but publication was delayed until a year after the end of World War II due to security concerns. At the Cavendish Laboratory in Cambridge, Egon Bretscher and Norman Feather realized that a slow neutron reactor fuelled with uranium would theoretically produce substantial amounts of plutonium-239 as a by-product. They calculated that element 94 would be fissile, and had the added advantage of being chemically different from uranium, and could easily be separated from it. McMillan had recently named the first transuranic element neptunium after the planet Neptune, and suggested that element 94, being the next element in the series, be named for what was then considered the next planet, Pluto.
==== Recombinant DNA ==== Biotechnology in the modern sense of genetic engineering began in the 1970s, with the invention of recombinant DNA techniques. Restriction enzymes were discovered and characterized in the late 1960s, following on the heels of the isolation, then duplication, then synthesis of viral genes. Beginning with the lab of Paul Berg in 1972 (aided by EcoRI from Herbert Boyer's lab, building on work with ligase by Arthur Kornberg's lab), molecular biologists put these pieces together to produce the first transgenic organisms. Soon after, others began using plasmid vectors and adding genes for antibiotic resistance, greatly increasing the reach of the recombinant techniques. Wary of the potential dangers (particularly the possibility of a prolific bacteria with a viral cancer-causing gene), the scientific community as well as a wide range of scientific outsiders reacted to these developments with both enthusiasm and fearful restraint. Prominent molecular biologists led by Berg suggested a temporary moratorium on recombinant DNA research until the dangers could be assessed and policies could be created. This moratorium was largely respected, until the participants in the 1975 Asilomar Conference on Recombinant DNA created policy recommendations and concluded that the technology could be used safely. Following Asilomar, new genetic engineering techniques and applications developed rapidly. DNA sequencing methods improved greatly (pioneered by Frederick Sanger and Walter Gilbert), as did oligonucleotide synthesis and transfection techniques.
List of British Jewish writers includes writers (novelists, poets, playwrights, journalists, authors of scholarly texts and others) from the United Kingdom and its predecessor states who are or were Jewish or of Jewish descent.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.